Achieving Hepatitis C Micro-Elimination in Chinese Injecting Drug Users: A Dynamic Network Modeling Study.

IF 4.7 3区医学 Q1 INFECTIOUS DISEASES

Infectious Diseases and Therapy Pub Date : 2025-01-01 Epub Date: 2024-12-11 DOI:10.1007/s40121-024-01084-0

Ying Chen, Yun Bao, Mengxia Yan, Huajie Jin, Kaijie Yao, Chi Zhang, Wen Li, Bin Wu

{"title":"Achieving Hepatitis C Micro-Elimination in Chinese Injecting Drug Users: A Dynamic Network Modeling Study.","authors":"Ying Chen, Yun Bao, Mengxia Yan, Huajie Jin, Kaijie Yao, Chi Zhang, Wen Li, Bin Wu","doi":"10.1007/s40121-024-01084-0","DOIUrl":null,"url":null,"abstract":"Introduction: The World Health Organization (WHO) has established objectives for eradicating the hepatitis C virus (HCV). People who inject drugs (PWID), a major driver of HCV transmission, are an essential part of China's hepatitis C elimination program. This study aimed to estimate the requisite screening and antiviral treatment levels to achieve these goals among people who inject drugs in China and identify the most cost-effective strategy.Methods: This study utilized models based on dynamic social networks to simulate HCV transmission and disease progression among people who inject drugs in China, incorporating a cost-effectiveness analysis from a healthcare perspective.Results: To achieve the WHO targets, a minimum screening and treatment rate of 10% is required to meet the mortality goal, while a 25% rate is necessary for the incidence goal. The most cost-effective strategy includes a 25% screening rate and a 95% treatment rate. Compared to no intervention, this approach significantly reduces costs by - $85,873.38 (95% CI - $94,311.16 to - $77,435.59) and adds 24.66 (95% CI 23.68 to - 25.64) quality-adjusted life years. The intervention is dominant, with a cost-effectiveness ratio of - $3482.29 (95% CI - $3982.73 to - $3020.11) per quality-adjusted life year.Conclusion: Achieving the WHO's hepatitis C virus elimination targets among people who inject drugs in China is feasible and cost-saving.","PeriodicalId":13592,"journal":{"name":"Infectious Diseases and Therapy","volume":" ","pages":"181-197"},"PeriodicalIF":4.7000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11782747/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious Diseases and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40121-024-01084-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/11 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The World Health Organization (WHO) has established objectives for eradicating the hepatitis C virus (HCV). People who inject drugs (PWID), a major driver of HCV transmission, are an essential part of China's hepatitis C elimination program. This study aimed to estimate the requisite screening and antiviral treatment levels to achieve these goals among people who inject drugs in China and identify the most cost-effective strategy.

Methods: This study utilized models based on dynamic social networks to simulate HCV transmission and disease progression among people who inject drugs in China, incorporating a cost-effectiveness analysis from a healthcare perspective.

Results: To achieve the WHO targets, a minimum screening and treatment rate of 10% is required to meet the mortality goal, while a 25% rate is necessary for the incidence goal. The most cost-effective strategy includes a 25% screening rate and a 95% treatment rate. Compared to no intervention, this approach significantly reduces costs by - $85,873.38 (95% CI - $94,311.16 to - $77,435.59) and adds 24.66 (95% CI 23.68 to - 25.64) quality-adjusted life years. The intervention is dominant, with a cost-effectiveness ratio of - $3482.29 (95% CI - $3982.73 to - $3020.11) per quality-adjusted life year.

Conclusion: Achieving the WHO's hepatitis C virus elimination targets among people who inject drugs in China is feasible and cost-saving.

查看原文本刊更多论文

中国注射吸毒者实现丙型肝炎微消除：动态网络模型研究。

导论：世界卫生组织（WHO）制定了根除丙型肝炎病毒（HCV）的目标。注射吸毒者（PWID）是丙型肝炎病毒传播的主要驱动因素，也是中国消除丙型肝炎规划的重要组成部分。本研究旨在估计在中国注射吸毒者中实现这些目标所需的筛查和抗病毒治疗水平，并确定最具成本效益的策略。方法：本研究利用基于动态社会网络的模型，模拟中国注射吸毒者中丙型肝炎病毒的传播和疾病进展，并从医疗保健角度进行成本-效果分析。结果：要实现世卫组织的目标，最低筛查和治疗率必须达到10%才能实现死亡率目标，最低筛查和治疗率必须达到25%才能实现发病率目标。最具成本效益的策略包括25%的筛查率和95%的治疗率。与无干预相比，该方法显著降低了85,873.38美元（95% CI为94,311.16美元至77,435.59美元）的成本，并增加了24.66年（95% CI为23.68美元至- 25.64美元）的质量调整寿命年。干预占主导地位，每个质量调整生命年的成本-效果比为- 3482.29美元（95% CI为- 3982.73美元至- 3020.11美元）。结论：实现世界卫生组织在中国注射吸毒者中消除丙型肝炎病毒的目标是可行的，并且节省了成本。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infectious Diseases and Therapy Medicine-Microbiology (medical)

CiteScore

8.60

自引率

1.90%

发文量

136

审稿时长

6 weeks

期刊介绍： Infectious Diseases and Therapy is an international, open access, peer-reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of infectious disease therapies and interventions, including vaccines and devices. Studies relating to diagnostic products and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to, bacterial and fungal infections, viral infections (including HIV/AIDS and hepatitis), parasitological diseases, tuberculosis and other mycobacterial diseases, vaccinations and other interventions, and drug-resistance, chronic infections, epidemiology and tropical, emergent, pediatric, dermal and sexually-transmitted diseases.